BRPI0913379A2 - formulações farmacêuticas sólidas compreendendo bibw 2992 - Google Patents

formulações farmacêuticas sólidas compreendendo bibw 2992

Info

Publication number: BRPI0913379A2
Authority: BR; Brazil
Prior art keywords: bibw; pharmaceutical formulations; solid pharmaceutical; solid; formulations
Prior art date: 2008-06-06

Application number

BRPI0913379A

Other languages

English (en)

Inventor

Roman Messerschmid

Thomas Friedl

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-06

Filing date

2009-06-05

Publication date

2015-11-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913379(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-05 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-11-24 Publication of BRPI0913379A2 publication Critical patent/BRPI0913379A2/pt

2020-03-31 Publication of BRPI0913379B1 publication Critical patent/BRPI0913379B1/pt

2021-03-30 Publication of BRPI0913379B8 publication Critical patent/BRPI0913379B8/pt

2021-05-25 Publication of BRPI0913379C1 publication Critical patent/BRPI0913379C1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0913379A 2008-06-06 2009-06-05 intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão BRPI0913379C1 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP08157800.7		2008-06-06
EP08157800		2008-06-06
EP09160297.9		2009-05-14
EP09160297		2009-05-14
PCT/EP2009/056944 WO2009147238A1 (en)	2008-06-06	2009-06-05	Solid pharmaceutical formulations comprising bibw 2992

Publications (4)

Publication Number	Publication Date
BRPI0913379A2 true BRPI0913379A2 (pt)	2015-11-24
BRPI0913379B1 BRPI0913379B1 (pt)	2020-03-31
BRPI0913379B8 BRPI0913379B8 (pt)	2021-03-30
BRPI0913379C1 BRPI0913379C1 (pt)	2021-05-25

Family

ID=40941955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0913379A BRPI0913379C1 (pt)	2008-06-06	2009-06-05	intermediário compactado compreendendo dimaleato de bibw 2992, na forma de um pó, e seu método de produção, mistura intermediária ou final, e formulações orais sólidas prontas para o uso/ingestão

Country Status (33)

Country	Link
US (1)	US8545884B2 (pt)
EP (1)	EP2299971B1 (pt)
JP (1)	JP5632367B2 (pt)
KR (1)	KR101641517B1 (pt)
CN (1)	CN102056589B (pt)
AR (1)	AR072062A1 (pt)
AU (1)	AU2009254574B2 (pt)
BR (1)	BRPI0913379C1 (pt)
CA (1)	CA2726472C (pt)
CL (1)	CL2010001275A1 (pt)
CO (1)	CO6280463A2 (pt)
CY (1)	CY1117895T1 (pt)
DK (1)	DK2299971T3 (pt)
EA (1)	EA022168B1 (pt)
EC (1)	ECSP10010650A (pt)
ES (1)	ES2588031T3 (pt)
HR (1)	HRP20161061T1 (pt)
HU (1)	HUE029863T2 (pt)
IL (1)	IL209054A (pt)
MA (1)	MA34030B1 (pt)
ME (1)	ME02478B (pt)
MX (1)	MX2010012939A (pt)
MY (1)	MY151240A (pt)
NZ (1)	NZ589568A (pt)
PE (1)	PE20100252A1 (pt)
PL (1)	PL2299971T3 (pt)
PT (1)	PT2299971T (pt)
RS (1)	RS54943B1 (pt)
SI (1)	SI2299971T1 (pt)
TW (1)	TWI453203B (pt)
UY (1)	UY31867A (pt)
WO (1)	WO2009147238A1 (pt)
ZA (1)	ZA201007805B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000078735A1 (de)	1999-06-21	2000-12-28	Boehringer Ingelheim Pharma Kg	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
US20090306101A1 (en) *	2005-11-11	2009-12-10	Flavio Solca	Combination treatment of cancer comprising egfr/her2 inhibitors
CA2833706C (en)	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
SI1981863T1 (sl)	2006-01-26	2013-01-31	Boehringer Ingelheim International Gmbh	Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
EP2068880B1 (en) *	2006-09-18	2012-04-11	Boehringer Ingelheim International GmbH	Method for treating cancer harboring egfr mutations
UY31867A (es)	2008-06-06	2010-01-29	Boehringer Ingelheim Int	Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
HRP20191005T1 (hr)	2009-07-06	2019-08-23	Boehringer Ingelheim International Gmbh	Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
NO2608792T3 (pt)	2010-08-26	2018-03-10
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
WO2014118197A1 (en)	2013-02-01	2014-08-07	Boehringer Ingelheim International Gmbh	Radiolabeled quinazoline derivatives
CN106279126B (zh) *	2013-07-16	2019-05-24	杭州普晒医药科技有限公司	阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
NO2699580T3 (pt)	2014-01-24	2018-02-24
CN105534920B (zh) *	2014-10-29	2020-07-10	江苏豪森药业集团有限公司	一种药物组合物及其制备方法
EP3023421A1 (en)	2014-11-21	2016-05-25	Sandoz Ag	Crystalline forms of afatinib dimaleate
CN105769804B (zh) *	2014-12-23	2019-04-30	上海复星星泰医药科技有限公司	一种阿法替尼片及其制备方法
CN105801568B (zh)	2015-01-15	2019-07-30	杭州普晒医药科技有限公司	阿法替尼一马来酸盐晶型及其制备方法和药物组合物
KR20180018551A (ko)	2015-06-12	2018-02-21	프레세니어스 카비 온콜로지 리미티드	아파티닙 유리 염기 및 아파티닙 디말레에이트의 다형체 형태
WO2017033107A1 (en)	2015-08-21	2017-03-02	Fresenius Kabi Oncology Ltd.	Pharmaceutical compositions comprising afatinib
EP3156047A1 (en) *	2015-10-12	2017-04-19	Sandoz Ag	Afatinib-containing formulation
CN105456222B (zh) *	2015-12-22	2019-03-26	河南润弘制药股份有限公司	马来酸阿法替尼片及其制备方法
EP3260114A1 (en) *	2016-06-21	2017-12-27	Omya International AG	Method for the production of a dosage form
EP3260115A1 (en) *	2016-06-21	2017-12-27	Omya International AG	Method for the production of a dosage form
CN106074427A (zh) *	2016-07-31	2016-11-09	合肥远志医药科技开发有限公司	一种马来酸阿法替尼片剂及其制备方法
JP7265985B2 (ja)	2016-11-17	2023-04-27	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
CN110325051A (zh) *	2017-01-24	2019-10-11	奥姆尼根研究有限责任公司	颗粒状饲料补充剂及其制造和使用方法
JP2020513006A (ja) *	2017-04-06	2020-04-30	ジョンソン、マッセイ、パブリック、リミテッド、カンパニーＪｏｈｎｓｏｎＭａｔｔｈｅｙＰｕｂｌｉｃＬｉｍｉｔｅｄＣｏｍｐａｎｙ	アファチニブジマレアートの新規形態
WO2019070698A1 (en)	2017-10-02	2019-04-11	Johnson Matthey Public Limited Company	Novel forms of ibrutinib
FI3758708T3 (fi)	2018-03-01	2025-02-18	Astrazeneca Ab	(2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
WO2019195827A1 (en)	2018-04-06	2019-10-10	Johnson Matthey Public Limited Company	Novel form of ibrutinib
WO2019209908A1 (en)	2018-04-25	2019-10-31	Johnson Matthey Public Limited Company	Crystalline forms of dasatinib
KR20210032431A (ko)	2018-07-17	2021-03-24	인스메드 인코포레이티드	루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
JP2026503035A (ja)	2023-01-06	2026-01-27	インスメッドインコーポレイテッド	新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000078735A1 (de)	1999-06-21	2000-12-28	Boehringer Ingelheim Pharma Kg	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10063435A1 (de)	2000-12-20	2002-07-04	Boehringer Ingelheim Pharma	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
US20030225079A1 (en)	2002-05-11	2003-12-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
CA2833706C (en) *	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
US20090306101A1 (en)	2005-11-11	2009-12-10	Flavio Solca	Combination treatment of cancer comprising egfr/her2 inhibitors
SI1981863T1 (sl)	2006-01-26	2013-01-31	Boehringer Ingelheim International Gmbh	Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
WO2007109178A2 (en) *	2006-03-16	2007-09-27	Pharmacyclics, Inc.	Indole derivatives as inhibitors of histone deacetylase
EP2068880B1 (en)	2006-09-18	2012-04-11	Boehringer Ingelheim International GmbH	Method for treating cancer harboring egfr mutations
UY31867A (es)	2008-06-06	2010-01-29	Boehringer Ingelheim Int	Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
EP2387401A1 (en)	2009-01-14	2011-11-23	Boehringer Ingelheim International GmbH	Method for treating colorectal cancer
HRP20191005T1 (hr)	2009-07-06	2019-08-23	Boehringer Ingelheim International Gmbh	Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
EP2509592A1 (en)	2009-12-07	2012-10-17	Boehringer Ingelheim International GmbH	Bibw 2992 for use in the treatment of triple negative breast cancer

2009
- 2009-06-04 UY UY0001031867A patent/UY31867A/es active IP Right Grant
- 2009-06-04 PE PE2009000775A patent/PE20100252A1/es active IP Right Grant
- 2009-06-05 AU AU2009254574A patent/AU2009254574B2/en active Active
- 2009-06-05 HU HUE09757619A patent/HUE029863T2/en unknown
- 2009-06-05 EP EP09757619.3A patent/EP2299971B1/en active Active
- 2009-06-05 MX MX2010012939A patent/MX2010012939A/es active IP Right Grant
- 2009-06-05 WO PCT/EP2009/056944 patent/WO2009147238A1/en not_active Ceased
- 2009-06-05 NZ NZ589568A patent/NZ589568A/xx unknown
- 2009-06-05 DK DK09757619.3T patent/DK2299971T3/en active
- 2009-06-05 MA MA33400A patent/MA34030B1/fr unknown
- 2009-06-05 PL PL09757619T patent/PL2299971T3/pl unknown
- 2009-06-05 CN CN2009801210803A patent/CN102056589B/zh active Active
- 2009-06-05 ES ES09757619.3T patent/ES2588031T3/es active Active
- 2009-06-05 ME MEP-2016-138A patent/ME02478B/me unknown
- 2009-06-05 MY MYPI20105644 patent/MY151240A/en unknown
- 2009-06-05 SI SI200931496A patent/SI2299971T1/sl unknown
- 2009-06-05 HR HRP20161061TT patent/HRP20161061T1/hr unknown
- 2009-06-05 TW TW098118819A patent/TWI453203B/zh active
- 2009-06-05 AR ARP090102042A patent/AR072062A1/es unknown
- 2009-06-05 CA CA2726472A patent/CA2726472C/en active Active
- 2009-06-05 RS RS20160573A patent/RS54943B1/sr unknown
- 2009-06-05 JP JP2011512146A patent/JP5632367B2/ja active Active
- 2009-06-05 US US12/995,715 patent/US8545884B2/en active Active
- 2009-06-05 EA EA201001852A patent/EA022168B1/ru active Protection Beyond IP Right Term
- 2009-06-05 KR KR1020107027340A patent/KR101641517B1/ko active Active
- 2009-06-05 BR BRPI0913379A patent/BRPI0913379C1/pt active IP Right Grant
- 2009-06-05 PT PT97576193T patent/PT2299971T/pt unknown
2010
- 2010-11-01 IL IL209054A patent/IL209054A/en active IP Right Grant
- 2010-11-01 ZA ZA2010/07805A patent/ZA201007805B/en unknown
- 2010-11-19 CL CL2010001275A patent/CL2010001275A1/es unknown
- 2010-12-01 EC EC2010010650A patent/ECSP10010650A/es unknown
- 2010-12-03 CO CO10152537A patent/CO6280463A2/es not_active Application Discontinuation
2016
- 2016-08-10 CY CY20161100790T patent/CY1117895T1/el unknown

Also Published As

Publication number	Publication date
AU2009254574B2 (en)	2014-07-03
BRPI0913379B8 (pt)	2021-03-30
ES2588031T3 (es)	2016-10-28
PL2299971T3 (pl)	2017-04-28
PT2299971T (pt)	2016-07-29
JP5632367B2 (ja)	2014-11-26
AU2009254574A1 (en)	2009-12-10
HUE029863T2 (en)	2017-04-28
NZ589568A (en)	2012-08-31
CA2726472C (en)	2017-10-03
EP2299971B1 (en)	2016-05-25
BRPI0913379B1 (pt)	2020-03-31
EA022168B1 (ru)	2015-11-30
KR101641517B1 (ko)	2016-07-29
EP2299971A1 (en)	2011-03-30
HRP20161061T1 (hr)	2016-10-21
EA201001852A1 (ru)	2011-06-30
ZA201007805B (en)	2011-07-27
CY1117895T1 (el)	2017-05-17
IL209054A0 (en)	2011-01-31
ECSP10010650A (es)	2011-02-28
IL209054A (en)	2015-07-30
KR20110025908A (ko)	2011-03-14
MA34030B1 (fr)	2013-03-05
PE20100252A1 (es)	2010-04-12
RS54943B1 (sr)	2016-11-30
WO2009147238A1 (en)	2009-12-10
SI2299971T1 (sl)	2016-09-30
CO6280463A2 (es)	2011-05-20
CL2010001275A1 (es)	2011-05-13
DK2299971T3 (en)	2016-08-29
AR072062A1 (es)	2010-08-04
CN102056589B (zh)	2013-09-25
HK1152478A1 (en)	2012-03-02
US8545884B2 (en)	2013-10-01
TWI453203B (zh)	2014-09-21
UY31867A (es)	2010-01-29
JP2011522011A (ja)	2011-07-28
MY151240A (en)	2014-04-30
MX2010012939A (es)	2010-12-15
TW201000472A (en)	2010-01-01
US20110142929A1 (en)	2011-06-16
CN102056589A (zh)	2011-05-11
CA2726472A1 (en)	2009-12-10
BRPI0913379C1 (pt)	2021-05-25
ME02478B (me)	2017-02-20

Publication	Publication Date	Title
BRPI0913379A2 (pt)	2015-11-24	formulações farmacêuticas sólidas compreendendo bibw 2992
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
BRPI0820381A2 (pt)	2015-05-19	Formulações farmacêuticas
LTC2140867I2 (lt)	2018-11-12	Farmacinė kompozicija
BRPI0810928A2 (pt)	2019-09-24	"composição farmacêutica"
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
DK3492069T3 (da)	2022-03-14	Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
BRPI0814188A2 (pt)	2014-10-14	Formulações
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
EP2185112A4 (en)	2012-01-18	Stabilized therapeutic compositions and formulations
PT2209464E (pt)	2014-09-05	Composição farmacêutica antimalárica
BRPI0820198A2 (pt)	2019-09-24	composições farmacêuticas
DK2271321T3 (da)	2012-08-27	Farmaceutisk sammensætning 271
BRPI0912656A2 (pt)	2016-01-26	formulação farmacêutica sólida
BRPI0823402A2 (pt)	2015-06-16	Formulações farmacêuticas de olmesartan
EP2156832A4 (en)	2010-11-24	PHARMACEUTICAL COMPOSITION
BRPI0913709A2 (pt)	2015-10-13	"formulação farmacêutica"
BRPI0820839A2 (pt)	2015-06-16	Composição farmacêutica

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2020-02-04	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-03-24	B09X	Republication of the decision to grant [chapter 9.1.3 patent gazette]
2020-03-31	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-03-30	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: REF. RPI 2569 DE 31/03/2020 QUANTO AO TITULO.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF